It describes them as most appropriate for patients who cannot tolerate GLP-1 medications, those with a GLP-1 contraindication such as personal or family history of medullary thyroid carcinoma, or people whose situation calls for a different metabolic pathway
MT-1 in subcutaneous implant formulation and documented significant increases in pain-free sun exposure time in EPP patients, with studies characterising reduced phototoxic reactions, improved quality of life, and clinically meaningful photoprotection in a patient population where even brief visible light exposure produces severe phototoxic pain
Subsequent increases in the permeability of the intestinal barrier in CKD patients promote the translocation of bacterial products of intestinal origin, such as LPS, uremic toxins, and cytokines, into the systemic circulation, resulting in local and systemic inflammation, as well as oxidative stress associated with CKD (Krukowski et al., 2023
Spironolactone-driven nocturia is mechanistically different from overactive bladder, but increased functional bladder capacity still reduces waking frequency
Semaglutide emerged from Novo Nordisks systematic GLP-1 analogue optimisation programme as the successor to liraglutide , incorporating structural modifications addressing the three principal pharmacokinetic vulnerabilities of native GLP-1: DPP-IV susceptibility at position 8 addressed by Aib8 alpha-aminoisobutyric acid substitution, proteolytic cleavage at position 34 addressed by Arg34Lys substitution, and the short half-life of unmodified GLP-1 analogues addressed by the C18 fatty diacid conjugation providing tighter albumin binding and longer half-life than liraglutides C16 fatty acid, producing the approximately one-week half-life enabling once-weekly subcutaneous administration
14 BriaudP.CarrollR
